Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

How I treat NTRK gene fusion-positive cancers.

Lassen U.

ESMO Open. 2019 Nov 25;4(Suppl 2):e000612. doi: 10.1136/esmoopen-2019-000612. eCollection 2019. Review.

2.

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.

Hong DS, Concin N, Vergote I, de Bono JS, Slomovitz BM, Drew Y, Arkenau HT, Machiels JP, Spicer J, Jones R, Forster M, Cornez N, Gennigens C, Johnson ML, Thistlethwaite FC, Rangwala RA, Ghatta S, Windfeld K, Harris JR, Lassen UN, Coleman RL.

Clin Cancer Res. 2019 Dec 3. pii: clincanres.2962.2019. doi: 10.1158/1078-0432.CCR-19-2962. [Epub ahead of print]

PMID:
31796521
3.

Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays.

Pfarr N, Kirchner M, Lehmann U, Leichsenring J, Merkelbach-Bruse S, Glade J, Hummel M, Stögbauer F, Lehmann A, Trautmann M, Kumbrink J, Jung A, Dietmaier W, Endris V, Kazdal D, Evert M, Horst D, Kreipe H, Kirchner T, Wardelmann E, Lassen U, Büttner R, Weichert W, Dietel M, Schirmacher P, Stenzinger A.

Genes Chromosomes Cancer. 2019 Oct 25. doi: 10.1002/gcc.22819. [Epub ahead of print]

PMID:
31652375
4.

Capture and Detection of Circulating Glioma Cells Using the Recombinant VAR2CSA Malaria Protein.

Bang-Christensen SR, Pedersen RS, Pereira MA, Clausen TM, Løppke C, Sand NT, Ahrens TD, Jørgensen AM, Lim YC, Goksøyr L, Choudhary S, Gustavsson T, Dagil R, Daugaard M, Sander AF, Torp MH, Søgaard M, Theander TG, Østrup O, Lassen U, Hamerlik P, Salanti A, Agerbæk MØ.

Cells. 2019 Aug 28;8(9). pii: E998. doi: 10.3390/cells8090998.

5.

An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer.

Morgensztern D, Karaseva N, Felip E, Delgado I, Burdaeva O, Dómine M, Lara P, Paik PK, Lassen U, Orlov S, Trigo J, Shomova M, Baker-Neblett K, Vasquez J, Wang X, Yan L, Mitrica I, DeYoung MP, Garrido P.

Lung Cancer. 2019 Oct;136:74-79. doi: 10.1016/j.lungcan.2019.08.011. Epub 2019 Aug 14.

PMID:
31446228
6.

A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer.

Cejalvo JM, Jacob W, Fleitas Kanonnikoff T, Felip E, Navarro Mendivil A, Martinez Garcia M, Taus Garcia A, Leighl N, Lassen U, Mau-Soerensen M, Adessi C, Michielin F, James I, Ceppi M, Hasmann M, Weisser M, Cervantes A.

ESMO Open. 2019 Jul 22;4(4):e000532. doi: 10.1136/esmoopen-2019-000532. eCollection 2019.

7.

Combining PARP inhibition with PD-1 inhibitors.

Lassen U.

Lancet Oncol. 2019 Sep;20(9):1196-1198. doi: 10.1016/S1470-2045(19)30509-1. Epub 2019 Aug 1. No abstract available.

PMID:
31378457
8.

A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24.

Mirza MR, Bergmann TK, Mau-Sørensen M, Christensen RD, Åvall-Lundqvist E, Birrer MJ, Jørgensen M, Roed H, Malander S, Nielsen F, Lassen U, Brøsen K, Bjørge L, Mäenpää J.

Cancer Chemother Pharmacol. 2019 Oct;84(4):791-798. doi: 10.1007/s00280-019-03917-z. Epub 2019 Aug 2.

PMID:
31375879
9.

Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study.

Nørøxe DS, Østrup O, Yde CW, Ahlborn LB, Nielsen FC, Michaelsen SR, Larsen VA, Skjøth-Rasmussen J, Brennum J, Hamerlik P, Poulsen HS, Lassen U.

Oncotarget. 2019 Jul 8;10(43):4397-4406. doi: 10.18632/oncotarget.27030. eCollection 2019 Jul 8.

10.

High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer.

Bertelsen B, Tuxen IV, Yde CW, Gabrielaite M, Torp MH, Kinalis S, Oestrup O, Rohrberg K, Spangaard I, Santoni-Rugiu E, Wadt K, Mau-Sorensen M, Lassen U, Nielsen FC.

NPJ Genom Med. 2019 Jun 21;4:13. doi: 10.1038/s41525-019-0087-6. eCollection 2019.

11.

Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients.

Viller Tuxen I, Barlebo Ahlborn L, Mau-Soerensen M, Staal Rohrberg K, Cilius Nielsen F, Oestrup O, Westmose Yde C, Richter Vogelius I, Lassen U.

Br J Cancer. 2019 Jul;121(2):125-130. doi: 10.1038/s41416-019-0491-9. Epub 2019 Jun 12.

PMID:
31186525
12.

Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma.

Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.

Mol Cell Proteomics. 2019 Jun;18(6):1270. doi: 10.1074/mcp.W119.001571. No abstract available.

13.

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.

Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.

Mol Cell Proteomics. 2019 Jun;18(6):1255-1268. doi: 10.1074/mcp.RA119.001524.

PMID:
31154438
14.

Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma.

Even C, Lassen U, Merchan J, Le Tourneau C, Soria JC, Ferte C, Ricci F, Diener JT, Yuen E, Smith C, Oakley GJ 3rd, Benhadji KA, Massard C.

Invest New Drugs. 2019 Apr 6. doi: 10.1007/s10637-019-00739-x. [Epub ahead of print]

PMID:
30953269
15.

Socioeconomic Differences in Referral to Phase I Cancer Clinical Trials: A Danish Matched Cancer Case-Control Study.

Gad KT, Johansen C, Duun-Henriksen AK, Krøyer A, Olsen MH, Lassen U, Mau-Sørensen M, Oksberg Dalton S.

J Clin Oncol. 2019 May 1;37(13):1111-1119. doi: 10.1200/JCO.18.01983. Epub 2019 Mar 12.

PMID:
30860947
16.

Application of cell-free DNA for genomic tumor profiling: a feasibility study.

Ahlborn LB, Rohrberg KS, Gabrielaite M, Tuxen IV, Yde CW, Spanggaard I, Santoni-Rugiu E, Nielsen FC, Lassen U, Mau-Sorensen M, Østrup O.

Oncotarget. 2019 Feb 15;10(14):1388-1398. doi: 10.18632/oncotarget.26642. eCollection 2019 Feb 15.

17.

Extracranial metastases in glioblastoma-Two case stories.

Schou Nørøxe D, Regner Michaelsen S, Broholm H, Møller S, Skovgaard Poulsen H, Lassen U.

Clin Case Rep. 2018 Dec 27;7(2):289-294. doi: 10.1002/ccr3.1980. eCollection 2019 Feb.

18.

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.

de Bono JS, Concin N, Hong DS, Thistlethwaite FC, Machiels JP, Arkenau HT, Plummer R, Jones RH, Nielsen D, Windfeld K, Ghatta S, Slomovitz BM, Spicer JF, Yachnin J, Ang JE, Mau-Sørensen PM, Forster MD, Collins D, Dean E, Rangwala RA, Lassen U.

Lancet Oncol. 2019 Mar;20(3):383-393. doi: 10.1016/S1470-2045(18)30859-3. Epub 2019 Feb 8. Erratum in: Lancet Oncol. 2019 Dec;20(12):e663.

PMID:
30745090
19.

Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Straten PT, Martinez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piro J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Lower M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Bruck A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rossler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Feb;566(7745):E13. doi: 10.1038/s41586-019-0959-z.

PMID:
30733620
20.

Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors.

Johansen MD, Urup T, Holst CB, Christensen IJ, Grunnet K, Lassen U, Friis S, Poulsen HS.

Cancer Invest. 2018;36(9-10):512-519. doi: 10.1080/07357907.2018.1544639.

PMID:
30727779
21.

Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Jan;565(7738):240-245. doi: 10.1038/s41586-018-0810-y. Epub 2018 Dec 19. Erratum in: Nature. 2019 Feb;566(7745):E13.

PMID:
30568303
22.

TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.

Kummar S, Lassen UN.

Target Oncol. 2018 Oct;13(5):545-556. doi: 10.1007/s11523-018-0590-1. Review.

PMID:
30276762
23.

Copenhagen Prospective Personalized Oncology (CoPPO)-Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials.

Tuxen IV, Rohrberg KS, Oestrup O, Ahlborn LB, Schmidt AY, Spanggaard I, Hasselby JP, Santoni-Rugiu E, Yde CW, Mau-Sørensen M, Nielsen FC, Lassen U.

Clin Cancer Res. 2019 Feb 15;25(4):1239-1247. doi: 10.1158/1078-0432.CCR-18-1780. Epub 2018 Oct 1.

PMID:
30274980
24.

Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors.

Ahlborn LB, Tuxen IV, Mouliere F, Kinalis S, Schmidt AY, Rohrberg KS, Santoni-Rugiu E, Nielsen FC, Lassen U, Yde CW, Oestrup O, Mau-Sorensen M.

Oncotarget. 2018 Aug 24;9(66):32570-32579. doi: 10.18632/oncotarget.25948. eCollection 2018 Aug 24.

25.

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.

Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.

Mol Cell Proteomics. 2018 Nov;17(11):2132-2145. doi: 10.1074/mcp.RA118.000792. Epub 2018 Aug 2. Retraction in: Mol Cell Proteomics. 2019 Jun;18(6):1270.

26.

First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer.

Massard C, Azaro A, Soria JC, Lassen U, Le Tourneau C, Sarker D, Smith C, Ohnmacht U, Oakley G, Patel BKR, Yuen ESM, Benhadji KA, Rodon J.

Ann Oncol. 2018 Sep 1;29(9):1911-1917. doi: 10.1093/annonc/mdy244.

PMID:
30060061
27.

VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance.

Michaelsen SR, Staberg M, Pedersen H, Jensen KE, Majewski W, Broholm H, Nedergaard MK, Meulengracht C, Urup T, Villingshøj M, Lukacova S, Skjøth-Rasmussen J, Brennum J, Kjær A, Lassen U, Stockhausen MT, Poulsen HS, Hamerlik P.

Neuro Oncol. 2018 Oct 9;20(11):1462-1474. doi: 10.1093/neuonc/noy103.

28.

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM.

N Engl J Med. 2018 Feb 22;378(8):731-739. doi: 10.1056/NEJMoa1714448.

29.

Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan.

Toft A, Urup T, Christensen IJ, Michaelsen SR, Lukram B, Grunnet K, Kosteljanetz M, Larsen VA, Lassen U, Broholm H, Poulsen HS.

Cancer Invest. 2018 Feb 7;36(2):165-174. doi: 10.1080/07357907.2018.1430818. Epub 2018 Feb 2. Review.

PMID:
29393706
30.

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.

Schneeweiss A, Park-Simon TW, Albanell J, Lassen U, Cortés J, Dieras V, May M, Schindler C, Marmé F, Cejalvo JM, Martinez-Garcia M, Gonzalez I, Lopez-Martin J, Welt A, Levy C, Joly F, Michielin F, Jacob W, Adessi C, Moisan A, Meneses-Lorente G, Racek T, James I, Ceppi M, Hasmann M, Weisser M, Cervantes A.

Invest New Drugs. 2018 Oct;36(5):848-859. doi: 10.1007/s10637-018-0562-4. Epub 2018 Jan 19.

31.

Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival.

Michaelsen SR, Urup T, Olsen LR, Broholm H, Lassen U, Poulsen HS.

J Neurooncol. 2018 May;137(3):533-542. doi: 10.1007/s11060-017-2739-7. Epub 2018 Jan 5.

PMID:
29305787
32.

A systematic review of targeted agents for non-small cell lung cancer.

Vestergaard HH, Christensen MR, Lassen UN.

Acta Oncol. 2018 Feb;57(2):176-186. doi: 10.1080/0284186X.2017.1404634. Epub 2017 Nov 25. Review.

PMID:
29172833
33.

A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors.

de Weger VA, Goel S, von Moos R, Schellens JHM, Mach N, Tan E, Anand S, Scott JW, Lassen U.

Cancer Chemother Pharmacol. 2018 Jan;81(1):73-80. doi: 10.1007/s00280-017-3469-4. Epub 2017 Nov 3.

PMID:
29101463
34.

Concordance of Mutation Detection in Circulating Tumor DNA in Early Clinical Trials Using Different Blood Collection Protocols.

Ahlborn LB, Madsen M, Jonson L, Nielsen FC, Lassen U, Yde CW, Mau-Sorensen M.

Clin Lab. 2017 Oct 1;63(10):1755-1759. doi: 10.7754/Clin.Lab.2017.170516.

PMID:
29035458
35.

Patient information in phase 1 trials: A systematic review.

Gad KT, Lassen U, Mau-Søerensen M, Høybye MT, Johansen C.

Psychooncology. 2018 Mar;27(3):768-780. doi: 10.1002/pon.4559. Epub 2017 Oct 26.

PMID:
28960785
36.

Hallmarks of glioblastoma: a systematic review.

Nørøxe DS, Poulsen HS, Lassen U.

ESMO Open. 2017 Feb 22;1(6):e000144. doi: 10.1136/esmoopen-2016-000144. eCollection 2016.

37.

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer.

Jacobsen K, Bertran-Alamillo J, Molina MA, Teixidó C, Karachaliou N, Pedersen MH, Castellví J, Garzón M, Codony-Servat C, Codony-Servat J, Giménez-Capitán A, Drozdowskyj A, Viteri S, Larsen MR, Lassen U, Felip E, Bivona TG, Ditzel HJ, Rosell R.

Nat Commun. 2017 Sep 4;8(1):410. doi: 10.1038/s41467-017-00450-6.

38.

Development in the number of clinical trial applications in Western Europe from 2007 to 2015: retrospective study of data from national competent authorities.

Dombernowsky T, Hædersdal M, Lassen U, Thomsen SF.

BMJ Open. 2017 Jul 10;7(7):e015579. doi: 10.1136/bmjopen-2016-015579.

39.

Clinical trial allocation in multinational pharmaceutical companies - a qualitative study on influential factors.

Dombernowsky T, Haedersdal M, Lassen U, Thomsen SF.

Pharmacol Res Perspect. 2017 May 19;5(3):e00317. doi: 10.1002/prp2.317. eCollection 2017 Jun.

40.

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.

Meulendijks D, Jacob W, Voest EE, Mau-Sorensen M, Martinez-Garcia M, Taus A, Fleitas T, Cervantes A, Lolkema MP, Langenberg MHG, De Jonge MJ, Sleijfer S, Han JY, Calles A, Felip E, Kim SW, Schellens JHM, Wilson S, Thomas M, Ceppi M, Meneses-Lorente G, James I, Vega-Harring S, Dua R, Nguyen M, Steiner L, Adessi C, Michielin F, Bossenmaier B, Weisser M, Lassen UN.

Clin Cancer Res. 2017 Sep 15;23(18):5406-5415. doi: 10.1158/1078-0432.CCR-17-0812. Epub 2017 Jun 9.

41.

Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients.

Urup T, Staunstrup LM, Michaelsen SR, Vitting-Seerup K, Bennedbæk M, Toft A, Olsen LR, Jønson L, Issazadeh-Navikas S, Broholm H, Hamerlik P, Poulsen HS, Lassen U.

BMC Cancer. 2017 Apr 18;17(1):278. doi: 10.1186/s12885-017-3251-3.

42.

Detection of copy number alterations in cell-free tumor DNA from plasma.

Østrup O, Ahlborn LB, Lassen U, Mau-Sørensen M, Nielsen FC.

BBA Clin. 2017 Apr 4;7:120-126. doi: 10.1016/j.bbacli.2017.03.006. eCollection 2017 Jun.

43.

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Plesner T, Arkenau HT, Gimsing P, Krejcik J, Lemech C, Minnema MC, Lassen U, Laubach JP, Palumbo A, Lisby S, Basse L, Wang J, Sasser AK, Guckert ME, de Boer C, Khokhar NZ, Yeh H, Clemens PL, Ahmadi T, Lokhorst HM, Richardson PG.

Blood. 2016 Oct 6;128(14):1821-1828. doi: 10.1182/blood-2016-07-726729. Epub 2016 Aug 16.

44.

Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients.

Urup T, Michaelsen SR, Olsen LR, Toft A, Christensen IJ, Grunnet K, Winther O, Broholm H, Kosteljanetz M, Issazadeh-Navikas S, Poulsen HS, Lassen U.

Mol Oncol. 2016 Oct;10(8):1160-8. doi: 10.1016/j.molonc.2016.05.005. Epub 2016 May 26.

45.

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors.

Abdul Razak AR, Mau-Soerensen M, Gabrail NY, Gerecitano JF, Shields AF, Unger TJ, Saint-Martin JR, Carlson R, Landesman Y, McCauley D, Rashal T, Lassen U, Kim R, Stayner LA, Mirza MR, Kauffman M, Shacham S, Mahipal A.

J Clin Oncol. 2016 Dec;34(34):4142-4150. Epub 2016 Oct 31.

46.

Comparison of (18)F-FET and (18)F-FLT small animal PET for the assessment of anti-VEGF treatment response in an orthotopic model of glioblastoma.

Nedergaard MK, Michaelsen SR, Perryman L, Erler J, Poulsen HS, Stockhausen MT, Lassen U, Kjaer A.

Nucl Med Biol. 2016 Mar;43(3):198-205. doi: 10.1016/j.nucmedbio.2015.12.002. Epub 2015 Dec 22.

47.

Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan.

Urup T, Dahlrot RH, Grunnet K, Christensen IJ, Michaelsen SR, Toft A, Larsen VA, Broholm H, Kosteljanetz M, Hansen S, Poulsen HS, Lassen U.

Acta Oncol. 2016;55(4):418-22. doi: 10.3109/0284186X.2015.1114679. Epub 2016 Feb 1.

PMID:
26828563
48.

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.

Meulendijks D, Jacob W, Martinez-Garcia M, Taus A, Lolkema MP, Voest EE, Langenberg MH, Fleitas Kanonnikoff T, Cervantes A, De Jonge MJ, Sleijfer S, Soerensen MM, Thomas M, Ceppi M, Meneses-Lorente G, James I, Adessi C, Michielin F, Abiraj K, Bossenmaier B, Schellens JH, Weisser M, Lassen UN.

Clin Cancer Res. 2016 Feb 15;22(4):877-85. doi: 10.1158/1078-0432.CCR-15-1683. Epub 2015 Oct 13.

49.

Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors.

Meulendijks D, Lassen UN, Siu LL, Huitema AD, Karanikas V, Mau-Sorensen M, Jonker DJ, Hansen AR, Simcox ME, Schostack KJ, Bottino D, Zhong H, Roessler M, Vega-Harring SM, Jarutat T, Geho D, Wang K, DeMario M, Goss GD, Schellens JH.

Clin Cancer Res. 2016 Feb 15;22(4):858-67. doi: 10.1158/1078-0432.CCR-15-1506. Epub 2015 Oct 7.

50.

Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma.

Persson M, Nedergaard MK, Brandt-Larsen M, Skovgaard D, Jørgensen JT, Michaelsen SR, Madsen J, Lassen U, Poulsen HS, Kjaer A.

J Nucl Med. 2016 Feb;57(2):272-8. doi: 10.2967/jnumed.115.161703. Epub 2015 Oct 1.

Supplemental Content

Loading ...
Support Center